Adjuvant versus Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer A Progress Report of a Phase-III Randomized Trial (Protocol CAO/ARO/AIO-94)

Explore this paper's citation graph

Summary

The patient accrual of the trial is satisfactory, neoadjuvant radiochemotherapy is well tolerated and bears no higher risk for postoperative morbidity, and primary endpoints include rate of curative (R0) resections and sphincter saving procedures, toxicity of radiochemistry, surgical complications and quality of life.

Type
article
Published
2001-03-01
Cited by
148
References
34

Keywords

Medicine, Total mesorectal excision, Colorectal cancer, Surgery, Radiation therapy

References

Cited by

Related papers